Literature DB >> 33509121

Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy.

Zhenli Zhu1, Tongqiang Zhang2,3, Wei Guo4, Yaoyao Ling1, Jiao Tian1, Yongsheng Xu5.   

Abstract

BACKGROUND: To observe the effect of corticosteroids in the treatment of children with refractory Mycoplasma pneumoniae pneumonia (RMPP) under different doses, to summarize the clinical features of children treated with glucocorticoid pulse therapy.
METHODS: The clinical data of 125 children with RMPP hospitalized in Tianjin Children's Hospital from September 2018 to October 2019 were retrospectively analyzed. They were divided into two groups according to the dose of hormone. Compare the clinical features, laboratory findings, and imaging between the two groups, and use meaningful related indicators as ROC curves to find reference indicators for pulse therapy.
RESULTS: (1) The median age of the group II was older than that of the group I(P < 0.05). (2) We found more severe presentations, higher incidence of extra-pulmonary complications and more serious radiological findings in group II, which needed oxygen more often, higher the hormone, higher usage rate of gamma globulin, higher usage rate of bronchoscopy, and higher incidence of plastic bronchitis(P < 0.05). (3) WBC, CRP, LDH, FER, D-D dimer, APTT, TT, PCT, IL-6 and the percentage of neutrophils in peripheral blood in Group II were higher than those in Group I(P < 0.05). (4) In ROC curve analysis, CRP, LDH, FER, and neutrophils of leukocyte classification were independent related factors that could be used as valuable predictors of methylprednisolone pulse therapy for RMPP in children. The cut-off values were CRP44.45 mg/L, LDH590IU/L, FER411ng/L, and neutrophils in leukocyte classification were 73.75%, respectively.
CONCLUSION: CRP ≥ 44.45 mg/L, LDH ≥ 590 IU/L, FER ≥ 411 ng/L, neutrophil≥73.75%, lung consolidation, and pleural effusion may be predictors that guide the treatment of RMPP with pulse dose of GC.

Entities:  

Keywords:  Children; Glucocorticoid; Mycoplasma pneumoniae pneumonia

Mesh:

Substances:

Year:  2021        PMID: 33509121      PMCID: PMC7844890          DOI: 10.1186/s12879-021-05830-4

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  51 in total

1.  Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children.

Authors:  Kyung-Yil Lee; Hyung-Shin Lee; Ja-Hyun Hong; Mi-Hee Lee; Joon-Sung Lee; David Burgner; Byung-Churl Lee
Journal:  Pediatr Pulmonol       Date:  2006-03

2.  Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia.

Authors:  Ryou Kawamata; Koji Yokoyama; Miori Sato; Masahide Goto; Yasuyuki Nozaki; Takeshi Takagi; Hideki Kumagai; Takanori Yamagata
Journal:  J Infect Chemother       Date:  2015-08-19       Impact factor: 2.211

3.  Bronchiolitis obliterans in the 1990s in Korea and the United States.

Authors:  C K Kim; S W Kim; J S Kim; Y Y Koh; A H Cohen; R R Deterding; C W White
Journal:  Chest       Date:  2001-10       Impact factor: 9.410

4.  Meta-analysis of the Clinical Efficacy and Safety of High- and Low-dose Methylprednisolone in the Treatment of Children With Severe Mycoplasma Pneumoniae Pneumonia.

Authors:  Lin-Li Sun; Chao Ye; Yu-Lu Zhou; Shan-Ru Zuo; Zhen-Zhen Deng; Chun-Jiang Wang
Journal:  Pediatr Infect Dis J       Date:  2020-03       Impact factor: 2.129

5.  [Clinical characteristics and predictive factors of refractory Mycoplasma pneumoniae pneumonia].

Authors:  Jin-rong Liu; Yun Peng; Hai-ming Yang; Hui-min Li; Shun-ying Zhao; Zai-fang Jiang
Journal:  Zhonghua Er Ke Za Zhi       Date:  2012-12

Review 6.  Necrotizing pneumonitis caused by Mycoplasma pneumoniae in pediatric patients: report of five cases and review of literature.

Authors:  Ruay-Shyang Wang; Shuo-Yu Wang; Kai-Sheng Hsieh; Yee-Hsuan Chiou; I-Fei Huang; Ming-Feng Cheng; Christine C Chiou
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

Review 7.  Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Jonathan C Craig; Guy D Eslick; Ian Seppelt; Anthony S McLean
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

8.  Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin.

Authors:  Achilleas Attilakos; Penelope Palaiologou; Evangelia Lagona; Aikaterini Voutsioti; Argirios Dinopoulos
Journal:  Pediatr Neurol       Date:  2008-05       Impact factor: 3.372

9.  [Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children].

Authors:  Lili Chen; Jinrong Liu; Shunying Zhao; Yungang Yang; Jinzhun Wu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2014-03

10.  More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.

Authors:  Yunlian Zhou; Yuanyuan Zhang; Yuanjian Sheng; Li Zhang; Zheng Shen; Zhimin Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more
  9 in total

1.  High Expression of MUC5AC, MUC5B, and Layilin Plays an Essential Role in Prediction in the Development of Plastic Bronchitis Caused by MPP.

Authors:  Yu Ma; Yeqi Gu; Xinxing Zhang; Wenjing Gu; Ting Wang; Huiming Sun; Yinfang Dai; Yongdong Yan; Yuqing Wang; Meijuan Wang; Huiquan Sun; Chuangli Hao; Liping Fan; Zhengrong Chen
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

2.  Clinical effect of reduning combined with gamma globulin treatment on symptom improvement serum levels of IL-6, 25-(OH)D and LDH in children with severe mycoplasma pneumonia.

Authors:  Xingna Ma; Wei Gao; Jinyu An
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

3.  Effects of Shenfu injection on inflammatory factors and immune function in children with Mycoplasma pneumoniae: A protocol for a double-blind, randomized controlled trial.

Authors:  Honglian Pei; Youfeng Ma; Lin Wang; Liping Wang; Li Xu; Rong Wang
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

4.  Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia.

Authors:  Qingchun Zhao; Junbo Yang; Yongmei Sheng; Min Zhuang; Min Qi
Journal:  J Healthc Eng       Date:  2022-03-27       Impact factor: 2.682

5.  Case Report and Literature Review: Clinical Characteristics of 10 Children With Mycoplasma pneumoniae-Induced Rash and Mucositis.

Authors:  Ning Chen; Miao Li
Journal:  Front Pediatr       Date:  2022-03-03       Impact factor: 3.418

6.  Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia.

Authors:  Soojeong Choo; Seo-Hee Kim; Eun Lee
Journal:  BMC Infect Dis       Date:  2022-05-16       Impact factor: 3.090

7.  Development and validation of a nomogram to predict plastic bronchitis in children with refractory Mycoplasma pneumoniae pneumonia.

Authors:  Lihua Zhao; Tongqiang Zhang; Xiaojian Cui; Linsheng Zhao; Jiafeng Zheng; Jing Ning; Yongsheng Xu; Chunquan Cai
Journal:  BMC Pulm Med       Date:  2022-06-27       Impact factor: 3.320

8.  Highly Expressed lncRNA GAS5 in the Serum of Children with Mycoplasma pneumoniae Pneumonia and Its Effect on LAMPs-Induced Apoptosis and Inflammation.

Authors:  Juhua Ji; Lei Song; Fei Hong; Weiyan Zhang; Meijun Zhu; Xiaohong Yang; Chuangli Hao
Journal:  Contrast Media Mol Imaging       Date:  2022-08-09       Impact factor: 3.009

9.  Case Report: Clinical Analysis of Fulminant Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Tongqiang Zhang; Chunjiao Han; Wei Guo; Jing Ning; Chunquan Cai; Yongsheng Xu
Journal:  Front Pediatr       Date:  2021-12-09       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.